KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 0.77.

  • Regeneron Pharmaceuticals' Equity Ratio fell 86.53% to 0.77 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.77, marking a year-over-year decrease of 86.53%. This contributed to the annual value of 0.77 for FY2025, which is 86.53% down from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Equity Ratio stood at 0.77, which was down 86.53% from 0.77 recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Equity Ratio high stood at 0.79 for Q1 2024, and its period low was 0.67 during Q1 2021.
  • For the 5-year period, Regeneron Pharmaceuticals' Equity Ratio averaged around 0.76, with its median value being 0.78 (2022).
  • Data for Regeneron Pharmaceuticals' Equity Ratio shows a peak YoY increase of 1580.9% (in 2021) and a maximum YoY decrease of 1247.62% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Equity Ratio stood at 0.74 in 2021, then grew by 5.13% to 0.78 in 2022, then increased by 1.21% to 0.79 in 2023, then decreased by 0.99% to 0.78 in 2024, then decreased by 0.87% to 0.77 in 2025.
  • Its last three reported values are 0.77 in Q4 2025, 0.77 for Q3 2025, and 0.78 during Q2 2025.